Contributions
Abstract: P944
Type: Poster Sessions
Abstract Category: Therapy - Tools for detecting therapeutic response
Background: Fingolimod and Dimethyl Fumarate (DMF) have been associated with immuno-modulation, promoting an anti-inflammatory state. The blood lipoprotein profile in patients with Multiple Sclerosis (MS) has previously been suggested to be associated with disease activity, with higher levels of high density lipoprotein (HDL) associated with lower inflammatory disease activity, while higher levels of low density lipoprotein (LDL), total cholesterol and triglycerides (TG) associated with worsening disability.
Aim: We aimed to assess whether Fingolimod or DMF therapy affects the lipoprotein profile of patients with MS.
Methods: We compared the blood lipid profiles before ,3 and 12 month (m) following treatment initiation in 27 patients treated with fingolimod and 34 patients treated with DMF therapy. All patients had no record of cholesterol-reducing medication before or during time of follow-up. Patients were asked about weight loss within 1 year of drug initiation.
Results: Fingolimod patients showed a mean 11.2% increase in HDL levels after 3m treatment, sustained and increased to 16% after 12m, a 8.1% increase in total cholesterol after 12m, while no change in LDL, TG and non-HDL cholesterol was observed. A 17.8% increase in HDL/LDL level was found after 3m, sustained throughout the follow-up. DMF patients showed a 13.6% increase in HDL levels after 3m, sustained throughout follow-up, with no change in other lipids, resulting in a 12.6% increase in the ratio of HDL/LDL after 3m. The majority (>81%) of patients did not experience any weight loss, thus weight reduction cannot explain the observed increase in HDL. We found no correlation between HDL increase and absolute lymphocytes count reduction in either group.
Conclusions: Fingolimod and DMF therapy are both associated with increased levels of HDL, while no change in other lipid levels was observed. This observation may be a beneficial side effect of the drugs and/or a biomarker of reduced inflammatory state. Whether increase in HDL correlates with clinical response to DMDs or cardiovascular risk remains to be determined in larger cohorts.
Disclosure: Elsebeth Staun-Ram: nothing to disclose
Shiri Blumenfeld Kan: nothing to disclose
Daniel Golan: nothing to disclose
Eitan Auriel: nothing to disclose
Ariel Miller: nothing to disclose
Abstract: P944
Type: Poster Sessions
Abstract Category: Therapy - Tools for detecting therapeutic response
Background: Fingolimod and Dimethyl Fumarate (DMF) have been associated with immuno-modulation, promoting an anti-inflammatory state. The blood lipoprotein profile in patients with Multiple Sclerosis (MS) has previously been suggested to be associated with disease activity, with higher levels of high density lipoprotein (HDL) associated with lower inflammatory disease activity, while higher levels of low density lipoprotein (LDL), total cholesterol and triglycerides (TG) associated with worsening disability.
Aim: We aimed to assess whether Fingolimod or DMF therapy affects the lipoprotein profile of patients with MS.
Methods: We compared the blood lipid profiles before ,3 and 12 month (m) following treatment initiation in 27 patients treated with fingolimod and 34 patients treated with DMF therapy. All patients had no record of cholesterol-reducing medication before or during time of follow-up. Patients were asked about weight loss within 1 year of drug initiation.
Results: Fingolimod patients showed a mean 11.2% increase in HDL levels after 3m treatment, sustained and increased to 16% after 12m, a 8.1% increase in total cholesterol after 12m, while no change in LDL, TG and non-HDL cholesterol was observed. A 17.8% increase in HDL/LDL level was found after 3m, sustained throughout the follow-up. DMF patients showed a 13.6% increase in HDL levels after 3m, sustained throughout follow-up, with no change in other lipids, resulting in a 12.6% increase in the ratio of HDL/LDL after 3m. The majority (>81%) of patients did not experience any weight loss, thus weight reduction cannot explain the observed increase in HDL. We found no correlation between HDL increase and absolute lymphocytes count reduction in either group.
Conclusions: Fingolimod and DMF therapy are both associated with increased levels of HDL, while no change in other lipid levels was observed. This observation may be a beneficial side effect of the drugs and/or a biomarker of reduced inflammatory state. Whether increase in HDL correlates with clinical response to DMDs or cardiovascular risk remains to be determined in larger cohorts.
Disclosure: Elsebeth Staun-Ram: nothing to disclose
Shiri Blumenfeld Kan: nothing to disclose
Daniel Golan: nothing to disclose
Eitan Auriel: nothing to disclose
Ariel Miller: nothing to disclose